Monday , June 21 2021

Expert explains why he’d take the Johnson & Johnson vaccine

Rocky Mountain Regional VA Medical Center investigational pharmacy technician Sara Berech prepares a dose of the Johnson & Johnson COVID-19 vaccine for a clinical trial on December 15, 2020 in Aurora, Colorado. Michael Ciaglo/Getty Images

Johnson & Johnson’s single-shot Covid-19 vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease, the company announced Friday.

The vaccine was 72% effective against moderate and severe disease in the US, the company said.

It’s a striking difference from vaccines from Pfizer/BioNTech and Moderna, and it may give pause to people uncertain about which vaccine to get or when they can get one. The vaccines already on the market in the US are about 95% effective overall against symptomatic Covid-19, with perhaps even higher efficacy against severe cases.

Experts say the Johnson & Johnson vaccine, developed by its vaccine arm Janssen, will still be useful against the pandemic in the United States and around the world, even if the single-dose vaccine doesn’t become the first choice for many.

For Johnson & Johnson, efficacy against moderate and severe ranged from one country to another: 72% in the US, 66% in Latin America and 57% in South Africa. This was measured from starting one month after the shot.

In South Africa, 95% of cases in the trial were due to a variant known as B.1.351, which is known to be more contagious and carries mutations that may make the virus less susceptible to the antibody immune response – including antibodies prompted by vaccination.

With that variant, “we have a lower protection against milder forms of Covid than we did in the United States, where there were more typical circulating variants,” Dr. Mathai Mammen, the company’s global head of research and development, told CNN’s Chief Medical Correspondent, Dr. Sanjay Gupta.

Even those who got moderate cases of Covid-19 in the trial tended to develop a milder course and fewer symptoms, he added.

But for Mammen, the key result was how effective the vaccine was at preventing severe disease – regardless of variant or age group.

“Across all geographies, across all variants, we see 85% protection” against severe disease, he said. That trend increased over time, with no severe cases in the vaccinated group after day 49, according to the company.

From one month after the shot, all hospitalizations and deaths occurred in the placebo group.

The results are based on an analysis of more than 44,000 participants in eight countries, with 468 total cases of Covid-19 split between those receiving the vaccine or placebo. The results have not been published in a peer-reviewed journal, but the company said it plans to do so “in the coming weeks.”

Johnson & Johnson is expected to apply to the US Food and Drug Administration next week for emergency use authorization, which Mammen said could come by late February.

close
Trending News

Sign up to receive Top trending , and keep up to date on our latest news!

We don’t spam! Read our privacy policy for more info.

About trendingnews

Check Also

‘Keeping Up With the Kardashians’ reunion: What we learned from Part II

There was a lot to cover, of course, given that their E! show has ended …

Leave a Reply

Your email address will not be published. Required fields are marked *